glp-1 fda approved New Pill Foundayo (Orforglipron) Gets Approval for Obesity FDA Approves Wegovy Alternative for

The TRIUMPH-4 trial protocol provides the best reference for effective dosing : Weeks 1-4: 2 mg once weekly (starting dose) Weeks 5-8: 4 mg once weekly Weeks 9-12: 6 mg once weekly Weeks 13-16: 8 mg once weekly Week 17+: 9 mg or 12 mg once weekly (maintenance dose) The escalation happens every 4 weeks, which is slightly faster than many tirzepatide protocols

174 Currently, Eli Lilly has initiated a Phase III development program to further investigate the efficacy and safety of orforglipron in treating obesity, overweight, and T2DM

Benjamin Bikman, Ph.D

In addition to improving satiety or fullness signaling in your brain, GLP-1s also affect your gut by slowing the rate at which you digest, process, and expel food waste